Alebund Pharmaceuticals Announces Poster Presentation by Partner R1 Therapeutics of Global Phase IIb Multi-Regional Clinical Trial Design for AP306 at ASN Kidney Week 2026
SHANGHAI, Oct. 23, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that its partner, R1 Therapeutics, Inc. ("R1"), presented a trial-in-progress poster outlining the design of the ongoing global Phase IIb multi-regional clinical trial of AP306, a first-in-class oral pan-phosphate transporter inhibitor, in patients with hyperphosphatemia receiving...
Angel Yeast Marks 40th Anniversary, Setting Its Sights on Becoming a Global Biotech Powerhouse
YICHANG, China, Oct. 23, 2026 /PRNewswire/ -- Angel Yeast (SSE: 600298), one of the world's leading yeast manufacturers, has hosted the 2026 International Synthetic Biology Symposium and the Angel Group High-Quality Development Conference in Yichang, its headquarters city, on October 19–20, 2026, as part of the company's 40th anniversary celebrations. ...
HoneyNaps Selected for 2026 Eurostars International R&D Project
Korean-Swedish consortium brings together Yonsei University, Dankook University, Uppsala University and Xantage AB Project to develop a non-invasive platform for neurological monitoring Skin-mounted sensors aim to track changes in intracranial pressure continuously, alongside sleep signal analysis BOSTON, Oct. 23, 2026 /PRNewswire/ -- HoneyNaps, a South Korean sleep medicine AI company, announced today that...
NUH OPHTHALMOLOGY AT 40: FOUR DECADES OF TRANSFORMING EYE CARE
The Department marks its anniversary by spotlighting innovations in multidisciplinary and minimally invasive care, alongside a flagship international congress that fosters global collaboration in ophthalmology SINGAPORE, Oct. 23, 2026 /PRNewswire/ -- As the Department of Ophthalmology at the National University Hospital (NUH) marks its 40th anniversary, it is advancing care for...
2026 CSCCP-ASCCP Colposcopy Training Course–Wuhan Station Concludes, Promoting More Precise and Non-Invasive Management of Cervical Lesions
Advancing Precision Diagnosis and Treatment Photodynamic Therapy Introduced for the First Time into Colposcopy Faculty Training in China WUHAN, China, Oct. 23, 2026 /PRNewswire/ -- The 2026 CSCCP-ASCCP Colposcopy Training Course, held in Wuhan from October 21 to 23, concluded successfully. Jointly organized by the Chinese Society for Colposcopy and Cervical Pathology (CSCCP) and the American...
Ping An Good Doctor’s Nine-Month Net Profit Rises 35%; Company Accelerates Efforts to Broaden AI Applications in Healthcare
HONG KONG and SHANGHAI, Oct. 23, 2026 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor" or the "Company"; Stock Code: 1833.HK) today announced its results for the nine months ended 30 September 2026. During the period, the Company recorded total revenue of RMB3.51billion and net profit of RMB0.25 billion, representing year-on-year growth of 35%....
ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology & Phase 2 Clinical Pipelines at BIO-Europe 2026
SEOUL, South Korea and COLOGNE, Germany, Oct. 23, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for rare and intractable diseases, today announced that its executive management team will participate in BIO-Europe 2026, held in Cologne, Germany, from November 9 to 11, 2026. ...
Carnyx Therapeutics Unveils Oral Sleep Candidate CNYX-005 with Preclinical Data Showing Increased NREM Sleep
Preclinical study shows 1.5- to 2-hour increase in total sleep time as Company advances toward clinical development and attracts Chris Brearley, M.D., as Chief Medical Officer INDIANAPOLIS, Oct. 23, 2026 /PRNewswire/ -- Carnyx Therapeutics Ltd. ("Carnyx" or the "Company"), a preclinical-stage biopharmaceutical company developing first-in-class molecular therapeutics for sleep and retinitis pigmentosa,...
Ascletis’ Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne
- With first patient dosed in Phase III clinical trial, Ascletis' strategic partner Sagimet Biosciences Inc. ("Sagimet") advances denifanstat (ASC40)'s U.S. registrational program, building on positive Phase III clinical results in China from Ascletis - Pivotal trial designed to enroll approximately 800 U.S. patients, including 450 adolescents aged 12 and older...
Harbour BioMed Receives China NMPA Approval of Batoclimab Injection (Subcutaneous Injection) for the Treatment of Generalized Myasthenia Gravis
The first NMPA-approved anti-FcRn therapy to complete its full clinical development for gMG patients in China CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Oct. 23, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other...
